

Received: Sat 3/27/2021 5:58:10 PM
 OBJECTIVES JOHANSEN March 26, 2021.ppt
 SPEAC_D2.5.2.1 Thrombocytopenia Case Definition Companion Guide V1.0 format.pdf
 CASE DEFINITION OF THROMBOSIS AND THROMBOEMBOLISM_DRAFT.docx

Dear Colleagues,

Thank you for attending the webinar yesterday and a special thank you to EMA, the EMA PRAC Rapporteur and the five EU/EEA MSs for sharing the next steps in the on-going investigations.

Please find the introductory slides to the webinar. You can here find an overview of which COVID-19 vaccine products are distributed by country and by age group. Not all but many EU/EEA countries report to the Vaccine tracker regularly displayed on the ECDC website and right now we are sincerely grateful that this information is available moving forward so adequate denominators can be used.

A follow-up webinar will be held next week to report from the EMA expert meeting to be held on the 29th of March and a quick tour de table for countries to report any new developments will also take place.

Meanwhile for countries that have initiated national studies feel free to share relevant information in response to this e-mail. I am also adding the two case definitions again from Brighton Collaboration that will become useful. But we heard there are already laboratory investigation initiated and information on those could be most helpful to other countries investigating cases. If methods already are in the public domain please share them.

Until soon,

5.1.2e

5.1.2e

EU/EEA NITAG COLLABORATION



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

5.1.2e

www.ecdc.europa.eu

Follow ECDC on:



-----Original Appointment-----

From: EU NITAG COLLABORATION

Sent: 23 March 2021 21:03

To: 5.1.2e @sozialministerium.at'; 5.1.2e @meduniwien.ac.at'; 5.1.2e @stpierre-bru.be';
 5.1.2e @sciensano.be'; 5.1.2e @hzjz.hr'; 5.1.2e @stampar.hr'; 5.1.2e
 5.1.2e @cytanet.com.cy'; 5.1.2e @szu.cz'; 5.1.2e @szu.cz'; 5.1.2e @sst.dk'; 5.1.2e @ssi.dk';
 5.1.2e @sm.ee'; 5.1.2e @terviseamet.ee'; 5.1.2e @thl.fi'; 5.1.2e ;
 5.1.2e @santepubliquefrance.fr'; 5.1.2e @rki.de'; 5.1.2e @uni-ulm.de'; 5.1.2e @med.uoa.gr';
 5.1.2e @gmail.com'; 5.1.2e @nnk.gov.hu'; 5.1.2e @olchc.ie'; 5.1.2e @hotmail.com';
 5.1.2e @hse.ie'; 5.1.2e @sanita.it'; 5.1.2e @apollo.lv'; 5.1.2e @spkc.gov.lv';
 5.1.2e @sam.lt'; 5.1.2e @sam.lt'; 5.1.2e @ms.etat.lu'; 5.1.2e @ms.etat.lu';
 5.1.2e @gov.mt'; 5.1.2e @gov.mt'; 5.1.2e @rivm.nl'; 5.1.2e @gr.nl'; 5.1.2e @fhi.no';
 5.1.2e @fhi.no'; 5.1.2e @pzh.gov.pl'; 5.1.2e @pzh.gov.pl'; 5.1.2e @dgs.min-saude.pt';
 5.1.2e @dgs.min-saude.pt'; 5.1.2e @arsnorte.min-saude.pt'; 5.1.2e @ms.ro'; 5.1.2e @insp.gov.ro';
 5.1.2e @insp.gov.ro'; 5.1.2e @uvzsr.sk'; 5.1.2e @jfmmed.uniba.sk'; 5.1.2e @nijz.si';
 5.1.2e @nijz.si'; 5.1.2e @mscbs.es'; 5.1.2e @mscbs.es'; 5.1.2e @phe.gov.uk';
 5.1.2e @phe.gov.uk'; 5.1.2e @folkhalsomyndigheten.se'; 5.1.2e @ncipd.org';
 5.1.2e @landlaeknir.is'; 5.1.2e @landlaeknir.is'; 5.1.2e @libero.it'; 5.1.2e ; 5.1.2e ; 5.1.2e

5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 5.1.2e @ema.europa.eu'; 5.1.2e @ema.europa.eu'; 5.1.2e @ec.europa.eu'; SANTE CONSULT-C3; 5.1.2e
 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e @folkhalsomyndigheten.se'; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 (5.1.2e @iss.it)'; 5.1.2e @iss.it'; 5.1.2e @llv.li'; 5.1.2e @guest.iss.it'; 5.1.2e @iss.it'; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; PHE Manager; PHE Technical
 Group; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; DL_VPI_COVID19Vaccine; DL_DP_CAI; 5.1.2e ;
 5.1.2e ; PHE Manager Assistant

Subject: Follow-up webinar on reported thromboembolic events following use of COVID-19 Vaccine AstraZeneca, Friday 26 March 11:00 –12:00

When: 26 March 2021 11:00-12:00 (UTC+01:00) Belgrade, Bratislava, Budapest, Ljubljana, Prague.

Where: ECDC 525

Dear Colleagues,

Please be invited to a

Follow-up Webinar on

Reported thromboembolic events following use of COVID-19 Vaccine AstraZeneca

Friday 26th of March 11:00 – 12:00 CET (line will stay open longer if needed)

Please extend the invitation to relevant EU/EEA NITAG Members and colleagues in public health or ministries of health with responsibilities for the COVID-19 vaccination programmes.

Please find dial-in details below.

A very warm welcome to all.

Programme

11:00 – 11:10	Welcome and objectives of the meeting	5.1.2e
11:10 – 11:30	Update from EMA on reported thromboembolic events following administration of the COVID-19 Vaccine AstraZeneca (other COVID-19 vaccines?)	5.1.2e 5.1.2e
11:30 – 11:55	Discussion	
11:55 – 12:00	Next steps	

**Please note that the meeting will be recorded for the purpose of the minutes.*

With kindest regards,

5.1.2e
5.1.2e

EU/EEA NITAG COLLABORATION

ECDC Emergency Operations Centre is inviting you to a scheduled Webex meeting.

Friday, March 26, 2021

11:00 AM | (UTC+01:00) Brussels, Copenhagen, Madrid, Paris | 1 hr

[Join meeting](#)

More ways to join:

5.1.2h

5 - 5

5.1.2h